Downregulation Of LncRNA PMS2L2 In Endometrial Adenocarcinoma Upon Carboplatin Treatment
Authors Zhang D, Sun X, Zhang Y
Received 29 June 2019
Accepted for publication 5 August 2019
Published 10 October 2019 Volume 2019:11 Pages 8905—8910
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Dr Eileen O'Reilly
Dan Zhang,1 Xiuyun Sun,1 Yuyang Zhang2
1Department of Gynaecology, General Hospital of Fushun Mining Bureau of Liaoning Health Industry Group, Fushun City, Liaoning Province 113008, People’s Republic of China; 2The Second Department of Oncology, General Hospital of Fushun Mining Bureau of Liaoning Health Industry Group, Fushun City, Liaoning Province 113008, People’s Republic of China
Correspondence: Yuyang Zhang
The Second Department of Oncology, General Hospital of Fushun Mining Bureau of Liaoning Health Industry Group, No.24 Central Street, Xinfu District, Fushun City, Liaoning Province 113008, People’s Republic of China
Tel +86 413 24-52533037
Background: LncRNA PMS2L2 plays critical protective roles in chondrocytes during lipopolysaccharide-induced inflammation. Our preliminary deep sequencing revealed the altered expression of PMS2L2 in endometrial adenocarcinoma (EA) during chemotherapy. This observation triggered our interest to explore the functions of PMS2L2 in EA.
Methods: Levels of PMS2L2 in plasma were measured by qPCR. ROC curve analysis was used for diagnostic analysis. Cell viability was analyzed by cell viability assay.
Results: We showed that plasma PMS2L2 was downregulated in EA patients compared with healthy controls, and downregulation of PMS2L2 distinguished early-stage EA patients from healthy controls. During carboplatin-based chemotherapy, plasma levels of PMS2L2 were significantly downregulated in endometrial cancer patients. Overexpression of PMS2L2 led to decreased viability of EA cells, while PMS2L2 siRNA silencing led to increased viability of EA cells.
Conclusion: LncRNA PMS2L2 in endometrial cancer was downregulated during carboplatin treatment and regulates chemosensitivity.
Keywords: endometrial adenocarcinoma, lncRNA PMS2L2, chemosensitivity, carboplatin
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]